Clofazimine: A useful antibiotic for drug-resistant tuberculosis

R Mirnejad, A Asadi, S Khoshnood, H Mirzaei, M Heidary, L Fattorini, A Ghodousi, D Darban-Sarokhalil

Research output: Contribution to journalArticle

Abstract

Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (DR) Mycobacterium tuberculosis (M. tuberculosis) strains have become the main challenge worldwide. Currently used antibiotics for treatment of DR-TB are often poorly tolerated and not sufficiently effective. Since the therapeutic options are still limited, the main strategy for treatment of DR-TB is to repurpose existing anti-mycobacterial agents. Clofazimine (CFZ) is one such drug that has recently attracted interest against DR-TB. CFZ is a hydrophobic riminophenazine that was initially synthesized as an anti-TB antibiotic. Although the mechanisms of action of CFZ are not yet entirely understood, it has been suggested that outer membrane is its primary action site, and the respiratory chain and ion transporters are the putative targets. In this review, we will discuss the anti-mycobacterial properties of CFZ, and provide new insights into the clinical use of this drug. © 2018 Elsevier Masson SAS
Original languageEnglish
Pages (from-to)1353-1359
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume105
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Clofazimine
Multidrug-Resistant Tuberculosis
Anti-Bacterial Agents
Tuberculosis
Electron Transport
Mycobacterium tuberculosis
Drug Resistance
Pharmaceutical Preparations
Ions
Membranes

Cite this

Mirnejad, R., Asadi, A., Khoshnood, S., Mirzaei, H., Heidary, M., Fattorini, L., ... Darban-Sarokhalil, D. (2018). Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomedicine and Pharmacotherapy, 105(4), 1353-1359. https://doi.org/10.1016/j.biopha.2018.06.023

Clofazimine: A useful antibiotic for drug-resistant tuberculosis. / Mirnejad, R; Asadi, A; Khoshnood, S; Mirzaei, H; Heidary, M; Fattorini, L; Ghodousi, A; Darban-Sarokhalil, D.

In: Biomedicine and Pharmacotherapy, Vol. 105, No. 4, 2018, p. 1353-1359.

Research output: Contribution to journalArticle

Mirnejad, R, Asadi, A, Khoshnood, S, Mirzaei, H, Heidary, M, Fattorini, L, Ghodousi, A & Darban-Sarokhalil, D 2018, 'Clofazimine: A useful antibiotic for drug-resistant tuberculosis', Biomedicine and Pharmacotherapy, vol. 105, no. 4, pp. 1353-1359. https://doi.org/10.1016/j.biopha.2018.06.023
Mirnejad R, Asadi A, Khoshnood S, Mirzaei H, Heidary M, Fattorini L et al. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomedicine and Pharmacotherapy. 2018;105(4):1353-1359. https://doi.org/10.1016/j.biopha.2018.06.023
Mirnejad, R ; Asadi, A ; Khoshnood, S ; Mirzaei, H ; Heidary, M ; Fattorini, L ; Ghodousi, A ; Darban-Sarokhalil, D. / Clofazimine: A useful antibiotic for drug-resistant tuberculosis. In: Biomedicine and Pharmacotherapy. 2018 ; Vol. 105, No. 4. pp. 1353-1359.
@article{d379c076552e4d0f87a8b8dfe28b49a7,
title = "Clofazimine: A useful antibiotic for drug-resistant tuberculosis",
abstract = "Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (DR) Mycobacterium tuberculosis (M. tuberculosis) strains have become the main challenge worldwide. Currently used antibiotics for treatment of DR-TB are often poorly tolerated and not sufficiently effective. Since the therapeutic options are still limited, the main strategy for treatment of DR-TB is to repurpose existing anti-mycobacterial agents. Clofazimine (CFZ) is one such drug that has recently attracted interest against DR-TB. CFZ is a hydrophobic riminophenazine that was initially synthesized as an anti-TB antibiotic. Although the mechanisms of action of CFZ are not yet entirely understood, it has been suggested that outer membrane is its primary action site, and the respiratory chain and ion transporters are the putative targets. In this review, we will discuss the anti-mycobacterial properties of CFZ, and provide new insights into the clinical use of this drug. {\circledC} 2018 Elsevier Masson SAS",
author = "R Mirnejad and A Asadi and S Khoshnood and H Mirzaei and M Heidary and L Fattorini and A Ghodousi and D Darban-Sarokhalil",
year = "2018",
doi = "10.1016/j.biopha.2018.06.023",
language = "English",
volume = "105",
pages = "1353--1359",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "4",

}

TY - JOUR

T1 - Clofazimine: A useful antibiotic for drug-resistant tuberculosis

AU - Mirnejad, R

AU - Asadi, A

AU - Khoshnood, S

AU - Mirzaei, H

AU - Heidary, M

AU - Fattorini, L

AU - Ghodousi, A

AU - Darban-Sarokhalil, D

PY - 2018

Y1 - 2018

N2 - Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (DR) Mycobacterium tuberculosis (M. tuberculosis) strains have become the main challenge worldwide. Currently used antibiotics for treatment of DR-TB are often poorly tolerated and not sufficiently effective. Since the therapeutic options are still limited, the main strategy for treatment of DR-TB is to repurpose existing anti-mycobacterial agents. Clofazimine (CFZ) is one such drug that has recently attracted interest against DR-TB. CFZ is a hydrophobic riminophenazine that was initially synthesized as an anti-TB antibiotic. Although the mechanisms of action of CFZ are not yet entirely understood, it has been suggested that outer membrane is its primary action site, and the respiratory chain and ion transporters are the putative targets. In this review, we will discuss the anti-mycobacterial properties of CFZ, and provide new insights into the clinical use of this drug. © 2018 Elsevier Masson SAS

AB - Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (DR) Mycobacterium tuberculosis (M. tuberculosis) strains have become the main challenge worldwide. Currently used antibiotics for treatment of DR-TB are often poorly tolerated and not sufficiently effective. Since the therapeutic options are still limited, the main strategy for treatment of DR-TB is to repurpose existing anti-mycobacterial agents. Clofazimine (CFZ) is one such drug that has recently attracted interest against DR-TB. CFZ is a hydrophobic riminophenazine that was initially synthesized as an anti-TB antibiotic. Although the mechanisms of action of CFZ are not yet entirely understood, it has been suggested that outer membrane is its primary action site, and the respiratory chain and ion transporters are the putative targets. In this review, we will discuss the anti-mycobacterial properties of CFZ, and provide new insights into the clinical use of this drug. © 2018 Elsevier Masson SAS

U2 - 10.1016/j.biopha.2018.06.023

DO - 10.1016/j.biopha.2018.06.023

M3 - Article

VL - 105

SP - 1353

EP - 1359

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 4

ER -